| Symbol | CAI |
|---|---|
| Name | CARIS LIFE SCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical Specialities |
| Address | 750 W. JOHN CARPENTER FREEWAY,SUITE 800, IRVING, Texas, 75039, United States |
| Telephone | (866) 771-8946 |
| Fax | — |
| — | |
| Website | www.carislifesciences.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002019410 |
| Description | Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Our current commercial product portfolio is focused on oncology and consists of MI Profile, our tissue-based molecular profiling solution that has generated the majority of our revenue to date, and Caris Assure, our novel, universal blood-based molecular profiling solution that was broadly launched in the first quarter of 2024 for therapy selection. Additional info from NASDAQ: |
Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026
Read moreNew Form CERT - Caris Life Sciences, Inc. <b>Filed:</b> 2026-06-16 <b>AccNo:</b> 0000876882-26-000010 <b>Size:</b> 445 KB
Read moreNew Form 8-A12B - Caris Life Sciences, Inc. <b>Filed:</b> 2026-06-16 <b>AccNo:</b> 0001104659-26-074436 <b>Size:</b> 15 KB
Read moreDirector POSTE GEORGE 🟢 acquired 1.6K shares of Caris Life Sciences, Inc. (CAI) at $15.62 Transaction Date: May 29, 2026 | Filing ID: 000003
Read moreDirector Knowles Jonathan Kenneth Charles 🟢 acquired 1.6K shares of Caris Life Sciences, Inc. (CAI) at $15.62 Transaction Date: May 29, 2026 | Filing ID: 000002
Read moreDenton John Russel 🔴 sold 6.0K shares of Caris Life Sciences, Inc. (CAI) at $15.25 Transaction Date: May 15, 2026 | Filing ID: 000005
Read morePower Luke Thomas 🔴 sold 9.8K shares of Caris Life Sciences, Inc. (CAI) at $15.25 Transaction Date: May 15, 2026 | Filing ID: 000004
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05692466 | Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Mole… | — | Stage III Solid Tumors | Unknown | 2023-02-01 | 2025-11-01 | ClinicalTrials.gov |
| NCT03834220 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE… | Phase2 | Solid Tumor | Terminated | 2019-03-22 | 2022-01-04 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| EORTC QLQ-30 | Other | Preclinical | Stage III Solid Tumors | UNKNOWN | NCT05692466 |
| Comprehensive molecular panel test | Other | Preclinical | Stage III Solid Tumors | UNKNOWN | NCT05692466 |
| Debio 1347 | Other | Phase PHASE2 | Solid Tumor | TERMINATED | NCT03834220 |